Kiniksa Pharmaceuticals (KNSA) Stock Statistics & Valuation Metrics

Kiniksa Pharmaceuticals has a market cap or net worth of $3.50B. The enterprise value is $3.29B.

Kiniksa Pharmaceuticals has 45,900,640 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kiniksa Pharmaceuticals’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 8.17%.

The current PE Ratio of Kiniksa Pharmaceuticals is 51.9. Kiniksa Pharmaceuticals’s PEG ratio is -0.22.

In the last 12 months, Kiniksa Pharmaceuticals had revenue of 677.56M and earned 59.01M in profits. Earnings per share was 0.80.

In the last 12 months, operating cash flow was 137.99M and capital expenditures -1.57M, giving a free cash flow of 136.42M billion.

Kiniksa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Kiniksa Pharmaceuticals upcoming earnings date is May 5, 2026, Before Open (Confirmed).

Kiniksa Pharmaceuticals as a current ratio of 3.79, with Debt / Equity ratio of 1.67%

In the past 12 months, Kiniksa Pharmaceuticals has paid 29.86M in taxes.

Kiniksa Pharmaceuticals EV to EBITDA ratio is 32.12, with an EV/FCF ratio of 114.30.

Kiniksa Pharmaceuticals has $414.07M in cash and marketable securities with $9.50M in debt, giving a net cash position of $404.58M billion.

Gross margin is 54.63%, with operating margin of 11.40%, and net profit margin of 8.71%.

The average price target for Kiniksa Pharmaceuticals is $57.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy